Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials

Langabeer, S. E., Walker, Helen, Rogers, J. R., Burnett, Alan Kenneth, Wheatley, K., Swirsky, D., Goldstone, A. H. and Linch, D. C. 1997. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. British Journal of Haematology 99 (4) , pp. 925-928. 10.1046/j.1365-2141.1997.4663270.x

Full text not available from this repository.


Acute myeloid leukaemia (AML) with the t(8;21)(q22;q22) is deemed to be a 'good-risk' disease. 396 patients with AML at diagnosis were screened for the presence of t(8;21) and AML1/ETO fusion transcripts by cytogenetic and RT-PCR techniques respectively. 32 cases of t(8;21) were detected, all of which were also PCR positive. A further 19 cases were detected at the molecular level, predominantly but not exclusively in M1 and M2 FAB types. Approximately 12% of all new cases of AML are estimated to have AML1/ETO fusion transcripts and it is suggested that molecular screening should be performed in all cases with the possible exception of the M3 FAB type.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RZ Other systems of medicine
Publisher: Wiley-Blackwell
ISSN: 0007-1048
Last Modified: 08 Jan 2020 03:22

Citation Data

Cited 99 times in Google Scholar. View in Google Scholar

Cited 73 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item